HESI LPN
Pharmacology HESI 2023
1. A client with a history of atrial fibrillation is prescribed sotalol. The nurse should monitor for which potential side effect?
- A. Bradycardia
- B. Tachycardia
- C. Headache
- D. Hyperglycemia
Correct answer: A
Rationale: Corrected Rationale: Sotalol, a medication used for atrial fibrillation, is known to cause bradycardia, which is a slower than normal heart rate. Monitoring the client's heart rate is essential to detect and manage this potential side effect promptly. Choice B, Tachycardia, is incorrect as sotalol is more likely to cause bradycardia. Choice C, Headache, and Choice D, Hyperglycemia, are unrelated side effects of sotalol and are not commonly associated with this medication.
2. A client with a history of deep vein thrombosis is prescribed edoxaban. The nurse should monitor for which potential adverse effect?
- A. Increased risk of bleeding
- B. Decreased risk of bleeding
- C. Increased risk of infection
- D. Decreased risk of infection
Correct answer: A
Rationale: The correct answer is A: Increased risk of bleeding. Edoxaban is an anticoagulant that works by inhibiting clot formation, thereby increasing the risk of bleeding. Therefore, the nurse should closely monitor the client for signs of bleeding, such as bruising, petechiae, hematuria, or gastrointestinal bleeding, to prevent potential complications. Choices B, C, and D are incorrect because edoxaban does not decrease the risk of bleeding or affect the risk of infection; its primary concern is the potential for bleeding due to its anticoagulant properties.
3. A client with chronic kidney disease is prescribed ferric citrate. The nurse should monitor for which potential side effect?
- A. Constipation
- B. Diarrhea
- C. Nausea
- D. Hyperphosphatemia
Correct answer: A
Rationale: When a client with chronic kidney disease is prescribed ferric citrate, the nurse should monitor for constipation as a potential side effect. Ferric citrate can lead to constipation due to its effects on the gastrointestinal system, causing a decrease in bowel movements. It is essential for the nurse to assess and manage constipation promptly to prevent complications and ensure the client's comfort and well-being. Monitoring bowel movements, providing adequate hydration, and recommending dietary interventions can help alleviate constipation in clients taking ferric citrate. Diarrhea, nausea, and hyperphosphatemia are not typically associated with the use of ferric citrate in clients with chronic kidney disease.
4. A client vomits 30 minutes after receiving a dose of hydromorphone on the first postoperative day. What initial intervention is best for the practical nurse (PN) to implement?
- A. Obtain a prescription for nasogastric intubation.
- B. Administer a prn dose of ondansetron.
- C. Reduce the next scheduled dose of hydromorphone.
- D. Assess the client's abdomen and bowel sounds.
Correct answer: B
Rationale: In this scenario, the client's vomiting is likely due to the hydromorphone administration, indicating a need for an antiemetic such as ondansetron to address the nausea. Nasogastric intubation (Choice A) is not necessary at this point as the client is vomiting, not experiencing an obstruction. While reducing the dose of hydromorphone (Choice C) may be considered later, the immediate focus should be managing the client's symptoms. Assessing the client's abdomen and bowel sounds (Choice D) can be important but is not the initial priority when addressing the vomiting post hydromorphone administration.
5. A client with a diagnosis of bipolar disorder is prescribed topiramate. The nurse should monitor for which potential adverse effect?
- A. Cognitive impairment
- B. Weight gain
- C. Liver toxicity
- D. Weight loss
Correct answer: A
Rationale: Correct. Topiramate is associated with cognitive impairment as an adverse effect. It is important for the nurse to monitor the client's cognitive function while on this medication to assess for any signs of cognitive decline or impairment. Choice B, weight gain, is incorrect as topiramate is actually associated with weight loss rather than weight gain. Choice C, liver toxicity, is also incorrect as topiramate is not known to cause liver toxicity. Choice D, weight loss, is not the correct answer as topiramate is not associated with weight gain.
Similar Questions
Access More Features
HESI LPN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All HESI courses Coverage
- 30 days access
HESI LPN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All HESI courses Coverage
- 30 days access